Crossmark

IL-6 as a biomarker in atezolizumab plus bevacizumab in patients with hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s00535-026-02360-1

Published Online: 2026-02-21

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Adnan, Maryam https://orcid.org/0000-0002-8438-2100
Khan, Saad https://orcid.org/0009-0006-3355-1062
Thasleem, Hiba https://orcid.org/0009-0003-3218-7105
Imran, Junaid https://orcid.org/0000-0001-6765-850X
Sohail, Fatima
License Information

Text and Data Mining valid from 2026-02-21

Version of Record valid from 2026-02-21
More Information

Article History

Received: 15 January 2025

Accepted: 4 February 2026

First Online: 21 February 2026

Declarations

:

: None.